盐酸坦洛新缓释胶囊治疗输尿管结石合并前列腺增生的临床分析

Clinical Analysis of Tamsulosin Hydrochloride Sustained-release Capsules in the Treatment of Ureteral Stones with Benign Prostatic Hyperplasia

目的探讨盐酸坦洛新缓释胶囊治疗输尿管结石合并前列腺增生的临床疗效。方法该次选择实验对象确定的时间为2017年9月—2018年9月,样本是随机选取该院接受治疗的60例输尿管结石合并前列腺增生的患者,随机将实验对象平分两组,每组30例,对患者应用盐酸消旋山莨菪碱注射液进行治疗的即为对照组,对患者采用盐酸坦洛新缓释胶囊治疗的即为观察组,两组患者的疗程均为1周,之后随访2周,对比两组样本的前列腺症状、排石率与不良反应。结果对照组患者排石率为66.67%,观察组患者排石率为76.67%,组间对比差异无统计学意义(χ^2=0.739,P=0.390>0.05)。两组患者在治疗前对比IPSS评分差异无统计学意义(P>0.05),在经过治疗后,观察组患者的IPSS评分明显低于治疗前,与对照组相比,其评分也明显低于对照组,差异有统计学意义(P<0.05),观察组患者的不良反应发生率为3.33%,而对照组患者的不良反应发生率较高为13.33%,差异有统计学意义(χ^2=6.002,P<0.05)。结论在临床治疗输尿管结石合并前列腺增生疾病时对患者采用盐酸坦洛新缓释胶囊治疗能够明显缓解患者的临床症状,有效排出患者体内的结石,患者一般预后状况良好,具有推广价值。

Objective To discuss the clinical efficacy of tanlosin hydrochloride sustained-release capsules in the treatment of ureteral stones with benign prostatic hyperplasia.Methods The selected time of this experiment was randomly election from September 2017 to September 2018.The sample was 60 patients with ureteral stones and benign prostatic hyperplasia who came to our hospital for treatment.The subjects were randomly divided into two groups.30 patients were treated with racemic anisodamine hydrochloride injection as the control group,and patients treated with tamsulosin hydrochloride sustained-release capsules as the observation group.The course of treatment in both groups was one week,after which Follow-up for two weeks,the prostate symptoms,stone rejection rate and adverse reactions were compared between the two groups of samples.Results The stone removal rate of the control group was 66.67%,and that of the observation group was 76.67%.There was no statistically significant difference between the groups(χ^2=0.739,P=0.390>0.05).There was no significant difference between the two groups of patients before treatment compared with the IPSS score(P>0.05).After treatment,the observation group’s IPSS score was significantly lower than before treatment,compared with the control group,its score was also significantly lower than the control Group,the difference was statistically significant(P<0.05),the incidence of adverse reactions in the observation group was 3.33%,while the incidence of adverse reactions in the control group was 13.33%,the difference was statistically significant(χ^2=6.002,P<0.05).Conclusion In the clinical treatment of ureteral stones with benign prostatic hyperplasia,the use of tanlosin hydrochloride sustained-release capsules for patients can significantly relieve the clinical symptoms of patients,effectively eliminate the stones in patients,and the patients generally have good prognosis and have promotion value.